FASL-844 T/C polymorphism: A biomarker of good prognosis of breast cancer in the Tunisian population

Human Immunology

Volumn 73, Issue 9, 2012, Pages 932-938

  Mahfoudh, Wijden ^a   Bouaouina, Noureddine ^a,b   Gabbouj, Sallouha ^a   Chouchane, Lotfi ^c  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUNISIA; YOUNG ADULT;

EID: 84865377829     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.06.001     Document Type: Article

References (46)

1. Curado MP, Edwards B, Shin HR. Cancer incidence in five continents, 2007 vol. IX. Lyon: IARC Scientific Publications.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. 2010. IARC Cancer Base No. 10, Lyon: International Agency for Research on Cancer. Available at http://globocan.iarc.fr.
3. Missaoui N., Jaidene L., Abdelkrim S.B., Abdelkader A.B., Beizig N., Yaacoub L.B., Yaacoubi M.T., Hmissa S. Breast cancer in Tunisia: clinical and pathological findings. Asian Pac J Cancer Prev 2011, 12:169-172.
4. Newman B., Austin M.A., Lee M., King M.C. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc. Natl. Acad. Sci. U. S. A. 1998, 85:3044-3048.
5. Claus E.B., Risch N., Thompson W.D. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet 1991, 48:232-242.
6. Antoniou A.C., Pharoah P.D., McMullan G., Day N.E., Stratton M.R., Peto J., Ponder B.J., Easton D.F. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002, 86:76-83.
7. Antoniou A.C., Pharoah P.P., Smith P., Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004, 91:1580-1590.
8. Antoniou A.C., Easton D.F. Models of genetic susceptibility to breast cancer. Oncogene 2006, 25:5898-5905.
9. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., Hemminki K. Environmental and heritable factors in the causation of cancer. N Engl J Med 2000, 343:78-85.
10. Houston A., O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004, 4:321-326.
11. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res 1997, 57:1007-1012.
12. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998, 160:5669-5675.
13. Mottolese M., Buglioni S., Bracalenti C., Cardarelli M.A., Ciabocco L., Giannarelli D., Botti C., Natali P.G., Concetti A., Venanzi F.M. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000, 89:127-132.
14. Takahashi T., Tanaka M., Inazawa J., Abe T., Suda T., Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994, 6:1567-1574.
15. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C., Cooke J., Xie F., Cooper G.S., Kimberly R.P. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003, 170:132-138.
16. Sun T., Zhou Y., Li H., Han X., Shi Y., Wang L., Miao X., Tan W., Zhao D., Zhang X., Guo Y., Lin D. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005, 202:967-974.
17. Zhang B., Sun T., Xue L., Han X., Zhang B., Lu N., Shi Y., Tan W., Zhou Y., Zhao D., Zhang X., Guo Y., Lin D. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007, 28:1067-1073.
18. Zhang Z., Qiu L., Wang M., Tong N., Li J., Zhang Z. The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009, 17:1294-1303.
19. Liu Y., Wen Q.J., Yin Y., Lu X.T., Pu S.H., Tian H.P., Lou Y.F., Tang Y.N., Jiang X., Lu G.S., Zhang J. FASLG polymorphism is associated with cancer risk. Eur J Cancer 2009, 45:2574-2578.
20. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
21. Sun T., Miao X., Zhang X., Tan W., Xiong P., Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004, 96:1030-1036.
22. Wang M., Wu D., Tan M., Gong W., Xue H., Shen H., Zhang Z. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 2009, 47:559-568.
23. Wang L.H., Ting S.C., Chen C.H., Tsai C.C., Lung O., Liu T.C., Lee C.W., Wang Y.Y., Tsai C.L. Lin YC (2010) Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 2010, 39:155-161.
24. Shao P., Ding Q., Qin C., Wang M., Tang J., Zhu J., Chen J., Cao Q., Li J., Xu B., Zhang Z., Zhang W., Yin C. Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 2011, 9999:1-9.
25. Zhu J., Qin C., Wang M., Yan F., Ju X., Meng X., Ding Q., Li P., Yang J., Cao Q., Zhang Z., Yin C. Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 2010, 49:810-817.
26. Zhou R.M., Wang N., Chen Z.F., Duan Y.N., Sun D.L. Li Y (2010) Polymorphisms in promoter region of FAS and FASL gene and risk of cardiac gastric adenocarcinoma. J Gastroenterol Hepatol 2010, 25:555-561.
27. Krippl P., Langsenlehner U., Renner W., Köppel H., Samonigg H. Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004, 96:1478-1479.
28. Crew K.D., Gammon M.D., Terry M.B., Zhang F.F., Agrawal M., Eng S.M., Sagiv S.K., Teitelbaum S.L., Neugut A.I., Santella R.M. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007, 28:2548-2551.
29. Chalabi N, Bernard-Gallon DJ, Bignon YJ; Breast Med Consortium, Kwiatkowski F, Agier M, Vidal V, Laplace-Chabaud V, Sylvain-Vidal V, Bertholet V, De Longueville F, Lacroix M, Leclercq G, Remacle J, Sibille C, Zammateo N, Ben Jaafar N, Sefiani A, Ouldim K, Mégarbané K, Jalkh N, Mahfoudh W, Troudi W, Ben Ammar-El Gaïed A, Chouchane L. Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences. Cancer Genomics Proteomics 2008; 5253-261.
30. Suzuki N., Wakisaka S., Takeba Y., Mihara S., Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999, 192:48-53.
31. Miñana J.B., Gómez-Cambronero L., Lloret A., Pallardó F.V., Del Olmo J., Escudero A., Rodrigo J.M., Pellíin A., Viña J.R., Viña J., Sastre J. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology 2002, 35:1205-1214.
32. Mor G., Kohen F., Garcia-Velasco J., Nilsen J., Brown W., Song J., Naftolin F. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000, 73:185-194.
33. Dong L., Wang W., Wang F., Stoner M., Reed J.C., Harigai M., Samudio I., Kladde M.P., Vyhlidal C., Safe S. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999, 274:32099-32107.
34. Zhang X., Miao X., Sun T., Tan W., Qu S., Xiong P., Zhou Y., Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005, 42:479-484.
35. Cao Y., Miao X.P., Huang M.Y., Deng L., Lin D.X., Zeng Y.X., Shao J.Y. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 2010, 49:944-950.
36. Lai H.C., Lin W.Y., Lin Y.W., Chang C.C., Yu M.H., Chen C.C., Chu T.Y. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005, 99:113-118.
37. Bebenek M, Duś D, Koźlak J. Fas and Fas ligand as prognostic factors in human breast carcinoma. Med Sci Monit 2006;12:CR457-461.
38. Reimer T., Herrnring C., Koczan D., Richter D., Gerber B., Kabelitz D., Friese K., Thiesen H.J. FasL:Fas ratio-a prognostic factor in breast carcinomas. Cancer Res 2000, 60:822-828.
39. Herrnring C., Reimer T., Jeschke U., Makovitzky J., Krüger K., Gerber B., Kabelitz D., Friese K. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 2000, 113:189-194.
40. O'Connell J., Bennett M.W., O'Sullivan G.C., O'Callaghan J., Collins J.K., Shanahan F. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol 1999, 6:457-463.
41. Ragnarsson G.B., Mikaelsdottir E.K., Vidarsson H., Jónasson J.G., Olafsdóttir K., Kristjánsdóttir K., Kjartansson J., Ogmundsdóttir H.M., Rafnar T. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer 2000, 83:1715-1721.
42. Pinti M., Troiano L., Nasi M., Moretti L., Monterastelli E., Mazzacani A., Mussi C., Ventura P., Olivieri F., Franceschi C., Salvioli G., Cossarizza A. Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ 2002, 9:431-438.
43. Jung J.H., Chae Y.S., Moon J.H., Kang B.W., Kim J.G., Sohn S.K., Park J.Y., Lee M.H., Park H.Y. TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 2010, 136:685-694.
44. Gerger A., Renner W., Langsenlehner T., Hofmann G., Knechtel G., Szkandera J., Samonigg H., Krippl P., Langsenlehner U. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 2010, 119:701-705.
45. Knechtel G., Hofmann G., Gerger A., Renner W., Langsenlehner T., Szkandera J., Wolf G., Samonigg H., Krippl P., Langsenlehner U. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol 2010, 136:1813-1819.
46. Park J.Y., Lee W.K., Jung D.K., Choi J.E., Park T.I., Lee E.B., Cho S., Park J.Y., Cha S.I., Kim C.H., Kam S., Jung T.H., Jheon S. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res 2009, 15:1794-1800.